ALCAM and cancer: Analysis of ALCAM immunoreactivity in cancer cells from metastases brought interesting results that were similar to ours because van Kempen et al. [9] identified ALCAM expression in 42 % (7/17) of the analyzed nodal metastatic foci while in our study we observed high expression (defined as IRS ≥8) in 5 out of 16 nodal metastatic foci (32 %).